About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

TNRCoverWeb120.jpg Buy on Amazon

Brain Waves

Monthly Archives

July 29, 2008

CollabRx - Arming You to Race for Your Cure

Email This Entry

Posted by Zack Lynch

collabrx.pngCasey, Dan and I met with Marty Tenenbaum founder of CollabRx and Tony Ley its CEO last week to get up to speed on their strategy for providing tools to patient groups and virtual biotechs to accelerate the development of treatments for diseases that don't attract major pharmaceutical company research funding. Today's WSJ details Marty's personal cancer stories and the goals of CollabRx. We discussed several ways that NIO and the broader neurotech research community could benefit from CollabRx. More on that as things get solidified. In the meantime, I highly recommend getting up to speed on the company. If anyone can instigate a sea change in this arena, it's Marty and the amazing ecosystem of relationships he wields.

Comments (0) + TrackBacks (0) | Category: Neuropharma

July 22, 2008

Allen Spinal Cord Atlas Debuts

Email This Entry

Posted by Zack Lynch

abif.pngThe Allen Institute for Brain Science on Thursday unveiled the Allen Spinal Cord Atlas, an online resource that shows how a mouse's complete set of 20,000 genes influences spinal cord development. The project should help scientists develop gene-based treatments and techniques to boost regeneration of damaged spinal cords.

Comments (0) + TrackBacks (0) | Category: Neurodiagnostics

July 2, 2008

Webcast of Entire Neural Interface Conference in June

Email This Entry

Posted by Zack Lynch

NICOHIO.pngIf you missed the 38th Neural Interface Conference in Ohio last month, you can see all the presentations via webcast here. The general structure of the conference focuses on the DBS for day one; day two focuses on neural prostheses for restoration of motor and sensory function; and day three describes advances in cochlear prostheses and therapeutic effects of stimulation.

Comments (0) + TrackBacks (0) | Category: Neurodevices

Nasdaq NeuroInsights Neurotech Index Update

Email This Entry

Posted by Zack Lynch

NERV0608.pngThe NASDAQ NeuroInsights Neurotech Index (NERV) underwent its biannual assessment resulting in the addition of three companies Adolor (ADLR), Noven (NOVN) and Somanetics (SMTS) and the loss of seven whose market cap dropped below the $200 million minimum, namely Alexza (ALXA), Aspect Medical (ASPM), Javelin (JAV), Micrus (MEND), Neurocrine (NBIX), Northstar Neuroscience (NSTR), and Vanda Pharmaceuticals (VNDA). Realtime quote of NERV.

Index Performance: As of June 30, historical back-testing indicates that ^NERV is up 9% from a theoretical start date of June 2005, compared to respective gains of 7.5% and 17% for the S&P 500 and the NASDAQ Biotech Index. The historical values prior to the Index launch are based on NASDAQ’s calculation of how the index may have performed over time if it existed. The back-tested Index Values are purely hypothetical and are solely for information purposes only. Back-tested Index Values do not represent actual Index performance and are not indicative of actual Index performance. The index began calculation on September 25, 2007.

Comments (0) + TrackBacks (0) | Category: NERV - Neurotech Index